BeyondSpring BYSI
NASDAQ BYSI
$0.72 +0.00 (+0.00%)
At close: Aug 21, 2026 · 4:00 PM EDT

BeyondSpring (BYSI) Liabilities and Shareholders Equity (2015 - 2026)

BeyondSpring (BYSI) posted Liabilities and Shareholders Equity of $18.4 million for Q1 2026, down 29.02% sequentially from $25.9 million in Q4 2025, and down 50.39% YoY from $37.1 million in Q1 2025.

BeyondSpring (BYSI) Liabilities and Shareholders Equity (2015 - 2026) Analysis & Trends

BeyondSpring has reported Liabilities and Shareholders Equity for 12 years, with the latest figure at $18.4 million in Q1 2026.

  • Quarterly Liabilities and Shareholders Equity fell 50.39% year-over-year to $18.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $104.9 million (up 13.59% YoY) and the FY2025 annual result came in at $25.9 million, down 24.43% from the prior year.
  • Liabilities and Shareholders Equity fell to $18.4 million in Q1 2026 per BYSI's latest filing, from $25.9 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $63.8 million in Q2 2022 and troughed at $18.4 million in Q1 2026.
  • A 5-year average of $33.2 million and a median of $31.0 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
  • The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity jumped 48.55% in 2025, then slumped 50.39% in 2026.
  • Over 5 years, Liabilities and Shareholders Equity stood at $46.2 million in 2022, then slumped by 46.33% to $24.8 million in 2023, then soared by 38.32% to $34.3 million in 2024, then slipped by 24.43% to $25.9 million in 2025, then slipped by 29.02% to $18.4 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $18.4 million, $25.9 million, and $29.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 10.03 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 10.96 Bn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 9.18 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 5.56 Bn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 25.60 Bn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 2.10 Bn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 19.82 Bn
10 BeyondSpring 29.85 Mn 29.85 Mn - 14.61 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 14.61 Mn
Mar 31, 2026 18.41 Mn
Dec 31, 2025 25.93 Mn
Sep 30, 2025 29.48 Mn
Jun 30, 2025 31.04 Mn
Mar 31, 2025 37.10 Mn
Dec 31, 2024 34.32 Mn
Jun 30, 2024 20.90 Mn
Dec 31, 2023 24.81 Mn
Jun 30, 2023 32.88 Mn
Dec 31, 2022 46.22 Mn
Jun 30, 2022 63.77 Mn
Dec 31, 2021 81.65 Mn
Sep 30, 2021 98.37 Mn
Jun 30, 2021 82.53 Mn
Mar 31, 2021 97.09 Mn
Dec 31, 2020 117.04 Mn
Sep 30, 2020 39.40 Mn
Jun 30, 2020 46.72 Mn
Mar 31, 2020 33.50 Mn